ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
-1.18 (-5.18%)
After Hours: 20.00 -1.62 (-7.49%)
Apr 15, 6:35PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.90 - 23.08
52 week 4.80 - 38.74
Open 23.08
Vol / Avg. 595,287.00/215,259.00
Mkt cap 208.65M
P/E     -
Div/yield     -
EPS -0.96
Shares 9.65M
Beta 2.30
Inst. own 61%

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 32.17% 0.35%
Operating margin 32.85% 2.99%
EBITD margin - 6.68%
Return on average assets 30.96% 0.36%
Return on average equity 35.00% -
Employees 23 -
CDP Score - -


United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. It performs contract manufacturing for other pharmaceutical companies. The Company has launched three products and has 11 products in development. Its targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Charlotte C. Arnold Chief Financial Officer, Vice President
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Bio & Compensation  - Reuters
Robert J. Jamnick Vice President - Quality and Product Development
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Bio & Compensation  - Reuters
Tracy L. Marshbanks Ph.D. Director
Bio & Compensation  - Reuters
Thomas A. Penn Director
Bio & Compensation  - Reuters
Daniel Raynor Director
Age: 53
Bio & Compensation  - Reuters
Fred H. Holubow Independent Director
Age: 74
Bio & Compensation  - Reuters